TY - JOUR
T1 - Safety assessment of probiotics for human use
AU - Sanders, Mary Ellen
AU - Akkermans, Louis M.A.
AU - Haller, Dirk
AU - Hammerman, Cathy
AU - Heimbach, James
AU - Hörmannsperger, Gabriele
AU - Huys, Geert
AU - Levy, Dan D.
AU - Lutgendorff, Femke
AU - Mack, David
AU - Phothirath, Phoukham
AU - Solano-Aguilar, Gloria
AU - Vaughan, Elaine
PY - 2010
Y1 - 2010
N2 - The safety of probiotics is tied to their intended use, which includes consideration of potential vulnerability of the consumer or patient, dose and duration of consumption, and both the manner and frequency of administration. Unique to probiotics is that they are alive when administered, and unlike other food or drug ingredients, possess the potential for infectivity or in situ toxin production. Since numerous types of microbes are used as probiotics, safety is also intricately tied to the nature of the specific microbe being used. The presence of transferable antibiotic resistance genes, which comprises a theoretical risk of transfer to a less innocuous member of the gut microbial community, must also be considered. Genetic stability of the probiotic over time, deleterious metabolic activities, and the potential for pathogenicity or toxicogenicity must be assessed depending on the characteristics of the genus and species of the microbe being used. Immunological effects must be considered, especially in certain vulnerable populations, including infants with undeveloped immune function. A few reports about negative probiotic effects have surfaced, the significance of which would be better understood with more complete understanding of the mechanisms of probiotic interaction with the host and colonizing microbes. Use of readily available and low cost genomic sequencing technologies to assure the absence of genes of concern is advisable for candidate probiotic strains. The field of probiotic safety is characterized by the scarcity of studies specifically designed to assess safety contrasted with the long history of safe use of many of these microbes in foods.
AB - The safety of probiotics is tied to their intended use, which includes consideration of potential vulnerability of the consumer or patient, dose and duration of consumption, and both the manner and frequency of administration. Unique to probiotics is that they are alive when administered, and unlike other food or drug ingredients, possess the potential for infectivity or in situ toxin production. Since numerous types of microbes are used as probiotics, safety is also intricately tied to the nature of the specific microbe being used. The presence of transferable antibiotic resistance genes, which comprises a theoretical risk of transfer to a less innocuous member of the gut microbial community, must also be considered. Genetic stability of the probiotic over time, deleterious metabolic activities, and the potential for pathogenicity or toxicogenicity must be assessed depending on the characteristics of the genus and species of the microbe being used. Immunological effects must be considered, especially in certain vulnerable populations, including infants with undeveloped immune function. A few reports about negative probiotic effects have surfaced, the significance of which would be better understood with more complete understanding of the mechanisms of probiotic interaction with the host and colonizing microbes. Use of readily available and low cost genomic sequencing technologies to assure the absence of genes of concern is advisable for candidate probiotic strains. The field of probiotic safety is characterized by the scarcity of studies specifically designed to assess safety contrasted with the long history of safe use of many of these microbes in foods.
KW - Antibiotic resistance
KW - Bifidobacterium
KW - FDA
KW - Health canada
KW - Lactobacillus
KW - PROSAFE
KW - Probiotic
KW - QPS
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=77954820449&partnerID=8YFLogxK
U2 - 10.4161/gmic.1.3.12127
DO - 10.4161/gmic.1.3.12127
M3 - Review article
C2 - 21327023
AN - SCOPUS:77954820449
SN - 1949-0976
VL - 1
SP - 164
EP - 185
JO - Gut Microbes
JF - Gut Microbes
IS - 3
ER -